natgillin/translations-raw huggingface dataset:
Sylvant has been investigated in one main study involving 79 adults with multicentric Castleman's disease who did not have HIV or HHV-8 infection. 
Zdravilo Sylvant so preiskovali v eni glavni študiji, ki je vključevala 79 odraslih z multicentrično Castlemanovo boleznijo, ki niso bili okuženi z virusom HIV ali HHV-8.
Patients with Castleman's disease produce too much IL-6 and this is thought to contribute to the abnormal growth of certain cells in the lymph nodes. 
Bolniki s Castlemanovo boleznijo proizvajajo preveč IL-6, to pa naj bi prispevalo k nenormalni rasti nekaterih celic v bezgavkah.
Castleman's disease is a disorder of the lymphatic system (a network of vessels that transport fluid from tissues through the lymph nodes and into the bloodstream) in which cells in lymph nodes start growing abnormally, causing benign tumours. 
Castlemanova bolezen je motnja limfnega sistema (mreže žil, po katerih se prenaša tekočina iz tkiv prek bezgavk in v krvni obtok), pri kateri začnejo celice v bezgavkah nenormalno rasti in s tem povzročajo benigne tumorje.
The most common side effects with Sylvant (which may affect more than 1 in 5 people) are infections (including upper respiratory tract infections such as those of the throat and nose), itching, rash, joint pain and diarrhoea. 
Najpogostejši neželeni učinki zdravila Sylvant (ki se lahko pojavijo pri več kot 1 od 5 bolnikov) so okužbe (vključno z okužbami zgornjih dihal, kot so okužbe grla in nosu), srbenje, izpuščaji, bolečine v sklepih in driska.
Sylvant is a medicine that is used to treat multicentric Castleman's disease in adults who are not infected with human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8). 
Sylvant je zdravilo, ki se uporablja za zdravljenje multicentrične Castlemanove bolezni pri odraslih, ki niso okuženi z virusom humane imunske pomanjkljivosti (HIV) in humanim virusom herpesa tipa 8 (HHV-8).
The active substance in Sylvant, siltuximab, is a monoclonal antibody. 
Učinkovina v zdravilu Sylvant, siltuksimab, je monoklonsko protitelo.
Symptoms can include tiredness, sweating at night, fever, peripheral neuropathy (pins and needles due to nerve damage) and swelling of liver and spleen. 
Simptomi lahko vključujejo utrujenost, nočno potenje, povišano telesno temperaturo, periferno nevropatijo (zbadanje zaradi okvare živcev) in otekanje jeter ter vranice.
For the full list of side effects and restrictions of Sylvant, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Sylvant glejte navodilo za uporabo.
It is given by infusion (drip) into a vein. 
Zdravilo se daje z infundiranjem (kapalno infuzijo) v veno.
By attaching to IL-6, siltuximab blocks its activity and stops abnormal cell growth, thus reducing the size of the lymph nodes and the symptoms of the disease. 
Siltuksimab z vezavo na IL-6 zavira njegovo delovanje in ustavi nenormalno rast celic ter s tem zmanjša velikost bezgavk in simptome bolezni.
How does Sylvant work? 
Kako zdravilo Sylvant deluje?
How is Sylvant used? 
Kako se zdravilo Sylvant uporablja?
Sylvant contains the active substance siltuximab. 
Zdravilo Sylvant vsebuje učinkovino siltuksimab.
The child should then be given water or milk to swallow the granules. 
Otroku nato damo vodo ali mleko, da zrnca pogoltne.
The dose is chosen to be lowest possible that controls the child's symptoms. 
Določiti je treba najmanjši možni odmerek, s katerim je še mogoče obvladovati otrokove simptome.
The capsules are opened and the granules are placed in the child's mouth. 
Kapsule odpremo in zrnca položimo v otrokova usta.
The granules can also be sprinkled on a spoonful of soft food and given to the child immediately. 
Zrnca lahko tudi posipamo na žlico mehke hrane in jih takoj damo otroku.
What measures are being taken to ensure the safe and effective use of Alkindi? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Alkindi?
It must also not be used in children with difficulty swallowing or in premature babies who haven't started feeding by mouth. 
Prav tako se ne sme uporabljati pri otrocih, ki imajo težave s požiranjem, ali pri nedonošenčkih, ki se še niso začeli hraniti preko ust.
The full EPAR for Alkindi can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Alkindi je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
This is a summary of the European public assessment report (EPAR) for Alkindi. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Alkindi.
A lack of the hormone causes several symptoms, including weight loss, muscle weakness, tiredness and low blood pressure. 
Pomanjkanje hormona povzroča več simptomov, vključno s hujšanjem, mišično oslabelostjo, utrujenostjo in nizkim krvnim tlakom.
As for every medicine, the company provided studies on the quality of Alkindi. 
Kot to velja za vsako zdravilo, je družba zagotovila študije o kakovosti zdravila Alkindi.
This means that it is similar to a ‘reference medicine' containing the same active substance (in this case Hydrocortisone Tablets Auden Mckenzie), but Alkindi is available in a different form (granules instead of tablets) and has been developed for children only. 
To pomeni, da je podobno referenčnemu zdravilu, ki vsebuje enako zdravilno učinkovino (v tem primeru tabletam hidrokortizona Auden Mckenzie), vendar je zdravilo Alkindi na voljo v drugačni obliki (v obliki zrnc in ne tablet) in je bilo razvito samo za otroke.
The European Medicines Agency concluded that the benefits of Alkindi are greater than its risks and recommended that it be approved for use in the EU. 
Evropska agencija za zdravila je zaključila, da so koristi zdravila Alkindi večje od z njim povezanih tveganj, in priporočila, da se odobri za uporabo v EU.
The company also carried out studies to show that it is ‘bioequivalent' to the reference medicine. 
Opravila je tudi študije, ki so pokazale, da je zdravilo biološko enakovredno referenčnemu zdravilu.
These include changes in behaviour, nausea, inflammation in the lining of the stomach and changes in blood potassium levels and excess acid in the blood. 
Ti so vključevali spremenjeno obnašanje, siljenje na bruhanje, vnetje želodčne sluznice in spremenjene ravni kalija v krvi ter povečano količino kisline v krvi.
Cortisol is needed to control many body processes (including inflammation and the control of sugar and mineral levels) and is sometimes referred to as the ‘stress hormone' because it helps the body respond to stress. 
Telo potrebuje kortizol za nadzor številnih procesov (vključno z vnetnimi procesi ter nadzorom ravni sladkorja in mineralov), imenujemo pa ga tudi „stresni hormon“, saj telesu pomaga pri odzivanju na stres.
Studies on the benefits and risks of the active substance have already been carried out with the reference medicine and do not need to be repeated for Alkindi. 
Študije o koristih in tveganjih zdravilne učinkovine so že bile izvedene z referenčnim zdravilom, zato jih ni treba ponoviti za zdravilo Alkindi.
For the full list of side effects see the package leaflet. 
Za celoten seznam neželenih učinkov glejte navodilo za uporabo.
Other information about Alkindi 
Druge informacije o zdravilu Alkindi
Alkindi is a medicine for children (from birth to up to 18 years of age) whose adrenal glands cannot make enough of a hormone called cortisol. 
Alkindi je zdravilo, namenjeno otrokom (od rojstva do starosti 18 let), pri katerih nadledvične žleze ne morejo izdelati dovolj hormona, imenovanega kortizol.
Alkindi is also available in a form suitable for children and it is easier to give a precise dose with Alkindi than with other treatments which require crushing tablets and weighing up the right dose. 
Zdravilo Alkindi je prav tako na voljo v obliki, primerni za otroke, zato ga je lažje natančno odmeriti kot druga zdravila, pri katerih sta potrebna drobljenje tablet in tehtanje pravilnega odmerka.
Alkindi is a ‘hybrid medicine'. 
Zdravilo Alkindi je „hibridno zdravilo“.
What is Alkindi and what is it used for? 
Kaj je zdravilo Alkindi in za kaj se uporablja?
What benefits of Alkindi have been shown in studies? 
Kakšne koristi je zdravilo Alkindi izkazalo v študijah?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Alkindi have been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Alkindi upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
Why is Alkindi approved? 
Zakaj je bilo zdravilo Alkindi odobreno?
What are the risks associated with Alkindi? 
Kakšna tveganja so povezana z zdravilom Alkindi?
Hydrocortisone replaces the natural cortisol that is missing in children whose adrenal glands do not produce enough of the hormone, thereby helping to relieve their symptoms. 
Hidrokortizon nadomešča naravni kortizol, ki ga otroci, pri katerih nadledvične žleze ne tvorijo dovolj hormona, nimajo, in tako lajša njihove simptome.
Alkindi is available as capsules containing granules. 
Zdravilo Alkindi je na voljo v obliki kapsul, ki vsebujejo zrnca.
Alkindi must not be used in patients with hypersensitivity (allergy) to the active substance or to any of the ingredients of Alkindi. 
Zdravila Alkindi ne smejo uporabljati bolniki s preobčutljivostjo za (alergijo na) zdravilno učinkovino ali katero koli sestavino zdravila Alkindi.
For more information about treatment with Alkindi, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Alkindi preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The active substance in Alkindi, hydrocortisone, is the same as cortisol, the main steroid hormone released by the body's adrenal gland. 
Zdravilna učinkovina v zdravilu Alkindi, hidrokortizon, je enaka kot kortizol, tj. glavni steroidni hormon, ki ga sprošča nadledvična žleza v telesu.
Alkindi produces similar levels of hydrocortisone in the blood to a reference medicine already authorised in the EU. 
Količina hidrokortizona, ki jo v krvi ustvari zdravilo Alkindi, je podobna kot pri referenčnem zdravilu, ki je že odobreno v EU.
It is not intended to provide practical advice on how to use Alkindi. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
For practical information about using Alkindi, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Alkindi naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
No side effects were reported in studies with Alkindi, but some side effects have been reported with other hydrocortisone medicines. 
Iz študij z zdravilom Alkindi niso poročali o nobenih neželenih učinkih, medtem ko so o določenih neželenih učinkih poročali pri drugih zdravilih, ki vsebujejo hidrokortizon.
How does Alkindi work? 
Kako zdravilo Alkindi deluje?
Alkindi contains the active substance hydrocortisone. 
Zdravilo Alkindi vsebuje zdravilno učinkovino hidrokortizon.
How is Alkindi used? 
Kako se zdravilo Alkindi uporablja?
on 9 August 2002. 
dne 9. avgusta 2002.
The Marketing Authorisation was subsequently renewed. 
Dovoljenje za promet je bilo kasneje podaljšano.
This summary was last updated in July 2007. 
Ta povzetek je bil nazadnje posodobljen 07-2007.
The studies were performed according to the requirements of the appropriate European Pharmacopoeia monographs. 
Študije so bile izvedene v skladu z zahtevami ustreznih monografij Evropske farmakopeje.
The onset of protection is from 2 weeks onwards and the protection extends to 9 weeks. 
Zaščita nastopi od drugega tedna dalje in traja do devet tednov.
The vaccine is also effective against Marek's disease. 
Cepivo je učinkovito tudi proti Marekovi bolezni.
The onset of protection is from 4 days onwards. 
Zaščita nastopi od četrtega dne dalje.
It is therefore recommended that no other vaccine than these should be administered within 14 days after vaccination with the product. 
Zato odsvetujemo uporabo kateregakoli cepiva v obdobju 14 dni po cepljenju s tem cepivom.
Studies have shown that the strain appears safe for turkeys, however precautionary measures should be followed in order to avoid direct or indirect contact between vaccinated chickens and turkeys. 
Študije so pokazale, da se zdi sev varen tudi za purane, vendar pa je kljub temu treba slediti varnostnim ukrepom, da bi se izognili neposrednemu ali posrednemu stiku med cepljenimi piščanci in purani.
The safety for non-susceptible bird species (pheasants, ducks, partridges, quails and pigeons) and for mammalian species (mice and guinea-pigs) was also demonstrated. 
Dokazana je bila tudi varnost pri neobčutljivih vrstah ptic (fazani, race, jerebice, prepelice in golobi) ter pri vrstah sesalcev (miši in morski prašički).
The safety of the product has been demonstrated in several laboratory and field trials in specific pathogen-free and other chickens. 
Varnost zdravila je bila dokazana v več laboratorijskih preizkusih in preizkusih na populaciji pri posebnih piščancih brez patogenov in drugih piščancih.
It is presented as a frozen suspension to be reconstituted with diluent and injected into chickens and into eggs where chicks are developing. 
Zdravilo je na voljo v obliki zamrznjene suspenzije, ki se jo rekonstituira z razredčilom in vbrizga v piščance ter jajca, v katerih se razvijajo piščanci.
As the product is stored in a tank under liquid nitrogen, particular instructions for reconstitution of the vaccine are provided in the product information module of the EPAR. 
Ker je zdravilo shranjeno v vsebniku s tekočim dušikom, so posebna navodila podana v modulu s podatki o zdravilu tega Evropskega javnega poročila o oceni zdravila (EPAR).
The product appears to show no interference with antibodies derived from the mother bird and can be safely administered to day-old chickens and chicks in the egg without presenting any apparent safety problem or inducing an immunosuppressive effect. 
Zdravilo ne kaže medsebojnega vplivanja s protitelesi, dobljenimi iz starševske ptice, in ga je mogoče varno vbrizgati tudi v en dan stare piščance ter piščance v jajcih brez varnostnih težav ali spodbujanja imunosupresivnega učinka.
No information is available on the safety and efficacy from the concurrent use with any other vaccine, except Merial attenuated vaccines against Marek's disease, Newcastle disease and Infectious bronchitis. 
Ni podatkov o varnosti ter učinkovitosti ob sočasni uporabi tega cepiva s katerimkoli drugim razen z Merialovim atenuiranim cepivom proti Marekovi bolezni, atipični kokošji kugi in infekcioznemu bronhitisu.
Whilst the vaccine is unlikely to affect male fertility, a warning has nevertheless been included in the SPC. 
Čeprav je učinek cepiva na plodnost samcev malo verjeten, je v Povzetek glavnih značilnosti zdravil (SPC) kljub temu vključeno tudi opozorilo.
Only healthy birds should be vaccinated and the product should not be used in birds in lay and breeding birds. 
Cepite lahko le zdrave ptice, cepiva pa ne smete uporabljati pri pticah v obdobju valjenja in za vzrejne ptice.
As for any turkey Herpesvirus (HVT) live vaccine, the product is excreted from vaccinated birds and may spread to turkeys. 
Kot velja za vsako živo cepivo puranjega herpesvirusa (HVT), lahko cepljene ptice izločajo cepivo, ki se lahko prenese na purane.
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Vaxxitek HVT+IBD exceed the risks of its use in chickens and recommended that Vaxxitek HVT+IBD be given a marketing authorisation. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je mnenja, da so koristni učinki uporabe zdravila Vaxxitek HVT+IBD pri piščancih večji od tveganj, zato priporoča odobritev dovoljenja za promet z zdravilom Vaxxitek HVT+IBD.
Vaxxitek HVT + IBD contains vaccine strains which induce an active immunity and a serological response (detected antibodies) against the two diseases. 
Zdravilo Vaxxitek HVT + IBD vsebuje cepne seve, ki spodbudijo aktivno imunost in serološki odziv (prisotnost protiteles) proti obema boleznima.
In the absence of specific studies, no other vaccine should be administered at the same time when the product is injected into eggs. 
Ker ni podatkov o posebnih študijah, se odsvetuje sočasna uporaba tega cepiva z drugimi cepivi, če ste ga vbrizgali v jajca.
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) VAXXITEK HVT+IBD EPAR summary for the public 
EMEA/V/C/065 EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) VAXXITEK HVT+IBD Povzetek EPAR za javnost
The studies demonstrated that Vaxxitek HVT+IBD is effective in the active immunisation of chickens and chicks in the egg against Infectious Bursal disease. 
Študije so dokazale, da je zdravilo Vaxxitek HVT+IBD učinkovito pri aktivni imunizaciji piščancev in nerojenih piščancev v jajcu na bolezen Gumboro.
Other information about Vaxxitek HVT+IBD: 
Druge informacije o zdravilu Vaxxitek HVT+IBD:
Information on the prescription status of this product may be found on the label/outer package. 
Podatke o predpisovanju tega zdravila so navedeni na nalepki na škatli zdravila.
The European Commission granted a marketing authorisation valid throughout the European Union, for Vaxxitek HVT+IBD to Merial S.A.S. 
Evropska komisija je dovoljenje za promet z zdravilom Vaxxitek HVT+IBD, veljavno po vsej Evropski uniji, odobrila družbi Merial S.A.S.
Vaxxitek HVT+IBD is also used to reduce mortality, clinical signs and effects of Marek's disease, a herpes virus infection of chickens. 
Zdravilo Vaxxitek HVT+IBD se uporablja tudi za zmanjšanje smrtnosti, ublažitev kliničnih znakov in učinkov Marekove bolezni, ki je okužba piščancev z virusom herpesa.
Vaxxitek HVT+IBD is used to prevent the deaths of chickens and to reduce clinical signs and effects of Infectious Bursal disease which is a disease which damages the immune system of chickens. 
Zdravilo Vaxxitek HVT+IBD se uporablja za preprečevanje smrtnosti piščancev in ublažitev kliničnih znakov in učinkov bolezni Gumboro, ki poškoduje imunski sistem piščancev.
What benefit has Vaxxitek HVT+IBD shown during the studies? 
Kakšne koristi je zdravilo Vaxxitek HVT+IBD izkazalo med raziskavami?
Vaxxitek HVT+IBD is a recombinant vaccine intended for use against Infectious Bursal Disease (also known as Gumboro Disease) and Marek's Disease in chickens. 
Zdravilo Vaxxitek HVT+IBD je rekombinantno cepivo, ki je namenjeno za uporabo proti bolezni Gumboro in Marekovi bolezni pri piščancih.
What is the risk associated with Vaxxitek HVT+IBD? 
Kakšna tveganja so povezana z zdravilom Vaxxitek HVT+IBD?
Why has Vaxxitek HVT+IBD been approved? 
Zakaj je bilo zdravilo Vaxxitek HVT+IBD odobreno?
What is Vaxxitek HVT+IBD? 
Kaj je zdravilo Vaxxitek HVT+IBD?
How has Vaxxitek HVT+IBD been studied? 
Kako je bilo zdravilo Vaxxitek HVT+IBD raziskano?
What is Vaxxitek HVT+IBD used for? 
Za kaj se zdravilo Vaxxitek HVT+IBD uporablja?
How does Vaxxitek HVT+IBD work? 
Kako zdravilo Vaxxitek HVT+IBD deluje?
The European Commission granted a marketing authorisation valid throughout the European Union for Pritor on 11 December 1998. 
Evropska komisija je dovoljenje za promet z zdravilom Pritor, veljavno po vsej Evropski uniji, izdala 11. decembra 1998.
What measures are being taken to ensure the safe and effective use of Pritor? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Pritor?
The full EPAR for Pritor can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Pritor je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Other information about Pritor 
Druge informacije o zdravilu Pritor
Pritor must not be used in women who are more than three months pregnant. 
Zdravila Pritor ne smejo uporabljati ženske, ki so noseče več kot tri mesece.
What benefit has Pritor shown during the studies? 
Kakšne koristi je zdravilo Pritor izkazalo med študijami?
Pritor is a medicine that contains the active substance telmisartan. 
Pritor je zdravilo, ki vsebuje zdravilno učinkovino telmisartan.
A risk management plan has been developed to ensure that Pritor is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Pritor je bil pripravljen načrt obvladovanja tveganj.
This is a summary of the European public assessment report (EPAR) for Pritor. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Pritor.
Pritor is used to treat essential hypertension (high blood pressure) in adults. 
Zdravilo Pritor se uporablja za zdravljenje esencialne hipertenzije (visokega krvnega tlaka) pri odraslih.
For more information about treatment with Pritor, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Pritor preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Pritor. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
The CHMP decided that Pritor's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Pritor večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Pritor, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
The active substance in Pritor, telmisartan, is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II. 
Zdravilna učinkovina v zdravilu Pritor, telmisartan, je „antagonist receptorjev angiotenzina II“, kar pomeni, da v telesu preprečuje delovanje hormona, imenovanega angiotenzin II.
What is the risk associated with Pritor? 
Kakšna tveganja so povezana z zdravilom Pritor?
Why has Pritor been approved? 
Zakaj je bilo zdravilo Pritor odobreno?
Hypotension may be more common in patients receiving Pritor to prevent cardiovascular problems. 
Hipotenzija je lahko pogostejša pri bolnikih, ki zdravilo Pritor jemljejo za preprečevanje srčno-žilnih težav.
For the prevention of cardiovascular problems, 80 mg Pritor once a day has been studied in one main study involving almost 26,000 patients aged 55 years or over who had heart or artery disease, had had a stroke, or had diabetes and were at high risk of cardiovascular problems. 
Za preprečevanje srčno-žilnih težav so zdravilo Pritor v odmerku 80 mg enkrat dnevno proučevali v eni glavni študiji, v katero je bilo vključenih skoraj 26 000 bolnikov, starih 55 let ali več, ki so imeli srčno ali arterijsko bolezen, so doživeli možgansko kap ali imeli sladkorno bolezen in pri katerih je obstajalo veliko tveganje za srčno-žilne težave.